DexTech Medical AB (XSAT:DEX) ROCE %: -33.28% (As of Mar. 2026)


XSAT:DEX DexTech Medical AB XSAT:DEX
32 GF Score
Price kr10.30
! 3 Warning Signs
View Full Analysis

What is DexTech Medical AB ROCE %?

DexTech Medical AB XSAT:DEX 32 ROCE % is -33.28% as of Mar. 2026. GuruFocus rates XSAT:DEX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. DexTech Medical AB's annualized ROCE % for the quarter that ended in Mar. 2026 was -33.28%.

DexTech Medical AB  (XSAT:DEX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

DexTech Medical AB ROCE % Related Terms

DexTech Medical AB ROCE % Historical Data

* Premium members only.

The historical data trend for DexTech Medical AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexTech Medical AB ROCE % Chart

DexTech Medical AB Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -60.43 -22.97 -13.50 -17.36 -19.56

DexTech Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.00 -24.60 -22.07 -29.09 -33.28
XSAT:DEX
32GF Score
DexTech Medical AB XSAT:DEX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexTech Medical AB ROCE % Calculation

DexTech Medical AB's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-5.318/( ( (30.588 - 0.98) + (25.1 - 0.337) )/ 2 )
=-5.318/( (29.608+24.763)/ 2 )
=-5.318/27.1855
=-19.56 %

DexTech Medical AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-6.992/( ( (22.315 - 0.44) + (20.679 - 0.535) )/ 2 )
=-6.992/( ( 21.875 + 20.144 )/ 2 )
=-6.992/21.0095
=-33.28 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -33.28% mean?
DexTech Medical AB (XSAT:DEX) has a ROCE % of -33.28% as of Mar. 2026.
Is DexTech Medical AB's ROCE % too high?
DexTech Medical AB's current ROCE % is -33.28%. Overall, DexTech Medical AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's ROCE % compare to VRTX and REGN?
DexTech Medical AB's ROCE % of -33.28% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. DexTech Medical AB's current ROCE % is -33.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (XSAT:DEX) has a current ROCE % of -33.28%. The current ROCE % is -33.28%. DexTech Medical AB's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For DexTech Medical AB (XSAT:DEX), the current ROCE % is -33.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DexTech Medical AB Business Description

Address Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
32GF Score

Get the complete analysis for XSAT:DEX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.30
Price